Literature DB >> 20104240

Hypertension: Cardiac hypertrophy as a target of antihypertensive therapy.

Alberto Zanchetti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20104240     DOI： 10.1038/nrcardio.2009.229

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  10 in total

Review 1.  Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced?

Authors:  Alberto Zanchetti
Journal:  J Hypertens       Date:  2009-08       Impact factor: 4.844

2.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

3.  Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease.

Authors:  Paolo Verdecchia; Peter Sleight; Giuseppe Mancia; Robert Fagard; Bruno Trimarco; Roland E Schmieder; Jae-Hyung Kim; Garry Jennings; Petr Jansky; Jyh-Hong Chen; Lisheng Liu; Peggy Gao; Jeffrey Probstfield; Koon Teo; Salim Yusuf
Journal:  Circulation       Date:  2009-09-21       Impact factor: 29.690

4.  Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document.

Authors:  Giuseppe Mancia; Stéphane Laurent; Enrico Agabiti-Rosei; Ettore Ambrosioni; Michel Burnier; Mark J Caulfield; Renata Cifkova; Denis Clément; Antonio Coca; Anna Dominiczak; Serap Erdine; Robert Fagard; Csaba Farsang; Guido Grassi; Hermann Haller; Anthony Heagerty; Sverre E Kjeldsen; Wolfgang Kiowski; Jean Michel Mallion; Athanasios Manolis; Krzysztof Narkiewicz; Peter Nilsson; Michael H Olsen; Karl Heinz Rahn; Josep Redon; José Rodicio; Luis Ruilope; Roland E Schmieder; Harry A J Struijker-Boudier; Pieter A van Zwieten; Margus Viigimaa; Alberto Zanchetti
Journal:  J Hypertens       Date:  2009-11       Impact factor: 4.844

5.  Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

Authors:  Johannes F E Mann; Roland E Schmieder; Matthew McQueen; Leanne Dyal; Helmut Schumacher; Janice Pogue; Xingyu Wang; Aldo Maggioni; Andrzej Budaj; Suphachai Chaithiraphan; Kenneth Dickstein; Matyas Keltai; Kaj Metsärinne; Ali Oto; Alexander Parkhomenko; Leopoldo S Piegas; Tage L Svendsen; Koon K Teo; Salim Yusuf
Journal:  Lancet       Date:  2008-08-16       Impact factor: 79.321

6.  Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients.

Authors:  Peter M Okin; Richard B Devereux; Katherine E Harris; Sverker Jern; Sverre E Kjeldsen; Stevo Julius; Jonathan M Edelman; Björn Dahlöf
Journal:  Ann Intern Med       Date:  2007-09-04       Impact factor: 25.391

7.  Telmisartan, ramipril, or both in patients at high risk for vascular events.

Authors:  Salim Yusuf; Koon K Teo; Janice Pogue; Leanne Dyal; Ingrid Copland; Helmut Schumacher; Gilles Dagenais; Peter Sleight; Craig Anderson
Journal:  N Engl J Med       Date:  2008-03-31       Impact factor: 91.245

8.  Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.

Authors:  S Yusuf; K Teo; C Anderson; J Pogue; L Dyal; I Copland; H Schumacher; G Dagenais; P Sleight
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321

9.  Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.

Authors:  Peter M Okin; Richard B Devereux; Sverker Jern; Sverre E Kjeldsen; Stevo Julius; Markku S Nieminen; Steven Snapinn; Katherine E Harris; Peter Aurup; Jonathan M Edelman; Hans Wedel; Lars H Lindholm; Björn Dahlöf
Journal:  JAMA       Date:  2004-11-17       Impact factor: 56.272

Review 10.  Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies.

Authors:  M R Law; J K Morris; N J Wald
Journal:  BMJ       Date:  2009-05-19
  10 in total
  9 in total

Review 1.  Antihypertensive therapy in 2014: Linking pathophysiology to antihypertensive treatment.

Authors:  Gianfranco Parati
Journal:  Nat Rev Cardiol       Date:  2015-01-13       Impact factor: 32.419

2.  Risk of hypertension and treatment on out-of-hospital cardiac arrest incidence: A case-control study.

Authors:  Jooyeong Kim; Sung-Il Cho; Jong-Hak Park; Juhyun Song; Sejoong Ahn; Hanjin Cho; Sungwoo Moon
Journal:  Medicine (Baltimore)       Date:  2022-06-03       Impact factor: 1.817

3.  Targeting Pim Kinases and DAPK3 to Control Hypertension.

Authors:  David A Carlson; Miriam R Singer; Cindy Sutherland; Clara Redondo; Leila T Alexander; Philip F Hughes; Stefan Knapp; Susan B Gurley; Matthew A Sparks; Justin A MacDonald; Timothy A J Haystead
Journal:  Cell Chem Biol       Date:  2018-07-19       Impact factor: 8.116

4.  Lactacystin-Induced Model of Hypertension in Rats: Effects of Melatonin and Captopril.

Authors:  Fedor Simko; Olga Pechanova; Kristina Repova; Silvia Aziriova; Kristina Krajcirovicova; Peter Celec; Lubomira Tothova; Stanislava Vrankova; Lucia Balazova; Stefan Zorad; Michaela Adamcova
Journal:  Int J Mol Sci       Date:  2017-07-25       Impact factor: 5.923

5.  OXY-SCORE: a new perspective for left ventricular hypertrophy diagnosis.

Authors:  Begoña Quintana-Villamandos; Laia Pazó-Sayós; Irene González Del Pozo; Pilar Rodríguez-Rodríguez; Jose María Bellón; Álvaro Pedraz-Prieto; Ángel G Pinto; Maria Carmen González
Journal:  Ther Adv Chronic Dis       Date:  2020-06-27       Impact factor: 5.091

6.  Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.

Authors:  Kyle Johnson; Suzanne Oparil; Barry R Davis; Larisa G Tereshchenko
Journal:  J Am Heart Assoc       Date:  2019-04-16       Impact factor: 5.501

Review 7.  Risk stratification of sudden cardiac death in hypertension.

Authors:  Larisa G Tereshchenko; Elsayed Z Soliman; Barry R Davis; Suzanne Oparil
Journal:  J Electrocardiol       Date:  2017-08-14       Impact factor: 1.438

8.  Mechanical stress triggers cardiomyocyte autophagy through angiotensin II type 1 receptor-mediated p38MAP kinase independently of angiotensin II.

Authors:  Li Lin; Chuyi Tang; Jianfeng Xu; Yong Ye; Liqing Weng; Wei Wei; Junbo Ge; Xuebo Liu; Yunzeng Zou
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.240

9.  Protective Effect of Vitis labrusca Leaves Extract on Cardiovascular Dysfunction through HMGB1-TLR4-NFκB Signaling in Spontaneously Hypertensive Rats.

Authors:  Hye Yoom Kim; Mi Hyeon Hong; Jung Joo Yoon; Dae Sung Kim; Se Won Na; Youn Jae Jang; Yun Jung Lee; Dae Gill Kang; Ho Sub Lee
Journal:  Nutrients       Date:  2020-10-11       Impact factor: 5.717
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.